Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Dr. Paul Kearney to the position of Chief Data Officer, effective October 1, 2021. As the chief data/analytics officer, Dr. Kearney will have responsibility to help direct, manage and analyze the large and growing data sets of Sera, both scientific and business, as Sera engages in studies designed to more fully characterize pregnancy and as commercial activities ramp during this phase of the company’s development.

“We are delighted to have Paul Kearney bring his extensive data science capabilities and experience to the Sera Prognostics team as we further our mission as The Pregnancy Company,” said Gregory C. Critchfield, M.D., M.S., Chairman and CEO of Sera Prognostics. “Paul’s deep experience and fundamental understanding of data will help Sera build a solid bridge at the intersection of business, healthcare, bioinformatics, and innovation, where critical societal and clinical unmet needs can be addressed through partnerships, data exploration, and individualized maternal and prenatal healthcare. These approaches are most pertinent for Sera to effectively address healthcare disparities and enormous challenges that exist in pregnancy.”

Prior to joining Sera Prognostics, Dr. Kearney co-founded multiple successful biotech companies and data enterprises, resulting in the development and commercialization of breakthrough products in the disease areas of oncology, pregnancy, and food allergy, as well as technological products in bioinformatics and proteomics. He has extensive experience building and nurturing integrated teams, conducting clinical research, developing evidence for improved health outcomes, and fund raising. Dr. Kearney has published over 100 papers in diverse areas and has been awarded over 12 patents. Previously, he worked in positions at the Institute for Systems Biology, Integrated Diagnostics, Caprion (now CellCarta), Data Incites, Bioinformatics Solutions, and AllerGenis. Dr. Kearney received his Ph.D. in Bioinformatics/Computer Science from the University of Toronto and was a member of the Computer Science Faculty of the University of Waterloo.